insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.

Blood 2025 Vol.146(21) p. 2608-2611

Raj R, Catueno S, Gibson A, McCall D, Garcia MB, Nunez C, Roth M, Sasaki K, Tewari P, Issa GC, Farhat A, Connors J, Sheikh I, Nishida Y, Yi JS, Stevens AM, Bataller A, Bhalla K, Petropoulos D, Daver N, Kadia T, Cuglievan B, DiNardo CD

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Raj R, Catueno S, et al. (2025). FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.. Blood, 146(21), 2608-2611. https://doi.org/10.1182/blood.2025029391
MLA Raj R, et al.. "FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.." Blood, vol. 146, no. 21, 2025, pp. 2608-2611.
PMID 40971491
DOI 10.1182/blood.2025029391

Abstract

FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline pediatric acute myeloid leukemia therapy. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes, and many proceeded to transplant. Common toxicities included cytopenias, comparable to previous regimens.

MeSH Terms

Humans; Sulfonamides; Leukemia, Myeloid, Acute; Bridged Bicyclo Compounds, Heterocyclic; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Male; Female; Child; Young Adult; Idarubicin; Vidarabine; Granulocyte Colony-Stimulating Factor; Child, Preschool; Adult; Infant